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How to measure quality of life for cost effectiveness analyses in personality 
disorders? A systematic review. 
 
Abstract 
Objective: To assess the construct validity and responsiveness of four generic health related 
quality of life (HRQL) measures in personality disorders (PDs). 
Methods: A systematic review was undertaken. Ten databases were searched and reference 
lists scrutinised to identify relevant studies. Relevant data were extracted accordingly. A narrative 
synthesis was performed of the evidence on construct validity including known groups validity 
(detecting differences in HRQL scores between two different groups), convergent validity 
(strength of association between generic HRQL and other measures (e.g. symptom) and 
responsiveness (differences in generic HRQL measure scores in responders/non-responders or 
correlation with changes in other measures).  
Results: Ten studies were identified, with 6 for the EQ-5D, two involving SF-36 and another 2 
the SF-12, but none on the SF-6D. Evidence indicated that the EQ-5D, SF-36 and SF-12 were 
probably valid measures within PDs. Four studies demonstrated that the EQ-5D Index was able 
to detect changes in patients. 
Conclusion: Generic HRQL measures appear appropriate for use in people with PDs in terms of 
psychometric performance. However, qualitative concerns remain as to whether they fully reflect 
the impact of the condition.  
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Introduction 
The effectiveness of mental health interventions can not be exclusively measured in terms of 
their ability to improve clinical outcomes such as reduction in symptom severity. The last decade 
has seen the increased use of economic evaluation and particularly cost effectiveness analyses 
to inform resource allocation decisions. This usually takes the form of health technology 
assessment reports submitted to agencies, for example, the National Institute of Clinical 
Excellence (NICE) in England, who advise governments on the treatments of choice and make 
decisions on which treatments to fund at a national level.  
  
The measurement of health-related quality of life (HRQL) fulfils a key role within economic 
evaluations. Health care policymakers require interventions to be assessed in terms of their cost 
per Quality Adjusted Life Year (QALY). The QALY is a way of measuring the benefits of health 
care interventions on a common scale and incorporating improvements in HRQL; thus taking into 
account improvements from the perspective of the patient. HRQL measures inform the ‘quality’ 
aspect of QALYs and the most commonly used method for putting the ‘q’ into the QALY is 
generic preference-based HRQL instruments such as the EQ-5D (Brooks, 1996; Rasanen et al., 
2006). Generic in this case means relevant to all patient groups, including those suffering from 
physical as well as those suffering from mental health problems. Preference-based HRQL 
measures have a multi-dimensional classification to define specific health states to which existing 
utility weights can be attached (McCrone et al., 2009); thus providing a valuation of each health 
state.  Utilities provide a value that indicates the strength of preference an individual has for a 
specific health state or outcome (Tolley, 2009).  The individual making the valuation can be the 
patient, clinician or the general population, though in the case of the EQ-5D it is a sample of the 
general population.  
 
There is strong evidence that interventions, such as psychotherapy, are clinically effective in 
personality disorders. A review by Bartak, Soeteman, Verheul and Busschbach (2007) found 
overwhelmingly positive evidence for the clinical effectiveness of psychotherapy for personality 
disorders, in the form of two meta-analyses (Leichsenring and Leibing, 2003; Perry, Banon and 
Ianni, 1999), six reviews (Gabbard, 2000; Ogrodniczuk and Piper, 2001; Perry and Bond, 2000; 
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Sainslow and McGlashan, 1998; Shea 1993; Bateman and Fonagy, 2000) and one Cochrane 
review (Binke et al., 2006). Treatments for PDs also appear to be cost-effective. Gabbard, Lazar, 
Hornberger and Spiegel (1997)reviewed the costs of psychotherapeutic treatment for personality 
disorders, and concluded that psychotherapy would lead to cost savings, attributable to 
reductions in inpatient treatments and decreases in work impairment.  
 
In general, studies in personality disorders present costs without explicitly relating them to the 
effects of an intervention (Bartak et al., 2007). Studies typically present the overall cost savings 
of one treatment in comparison to another (Ranger et al., 2009; Abbass, Sheldon, Gyra and 
Kalpin, 2008; Stevenson and Meares, 1999) or occasionally qualify the cost of the intervention in 
terms of an outcome or event avoided (e.g. costs per avoided parasuicide event were presented 
in six trials included in a health technology assessment on psychological therapies in borderline 
personality disorder) (Brazier et al., 2006).  
 
More recently, cost-effectiveness analyses have been published that provide policymakers with 
the preferred outcome of cost per QALY gained. For example, three studies used the EQ-5D to 
calculate the cost per QALY gained to measure the cost-effectiveness of psychotherapy in 
cluster B personality disorders (Soeteman et al., 2010), schema- or transference-focused 
psychotherapy in borderline personality disorder (van Asselt et al., 2008) and cognitive 
behavioural therapy  for borderline personality disorder (Palmer et al., 2006).  There has also 
been one study that used the SF-6D to evaluate the cost effectiveness of psychoanalysis versus 
psychoanalytic therapy (Berghout, Zevalkink, Hakkaart-van Roijen, 2010). However, the 
psychometric properties of generic HRQL measures in this patient group are largely unknown, 
and in general doubts have been raised about the appropriateness of generic measures in 
mental health (Brazier, 2010).. Whilst, it is claimed that the EQ- 5D and other ‘generic’ measures 
such as the SF-6D are applicable to all interventions and patient groups, including many physical 
conditions where these instruments have managed to pass psychometric tests of reliability and 
validity (Marra et al., 2005);  it is unknown if generic HRQL measures can ‘measure what they 
are intended to measure’ (i.e. are valid) and can detect changes in HRQL in patients when a 
change in severity in personality disorders has occurred (i.e. are responsive).  
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Systematic reviews of generic HRQL measures have been undertaken to determine what or if 
any evidence exists for their validity and responsiveness in physical health conditions e.g. vision 
(Tosh, Brazier, Evans and Longworth, 2012) and mental health conditions  e.g. schizophrenia 
(Papaioannou, Brazier and Parry, 2011). Such reviews have found mixed evidence on the 
validity and responsiveness of generic HQRL measures in a particular condition. In addition, 
reviews have also identified a lack of evidence for particular generic HRQL measures e.g.SF-6D.  
 
This is the first attempt  to systematically review the literature to identify if evidence exists to 
demonstrate that generic measures are valid and responsive in measuring HRQL in personality 
disorders. Four generic HRQL measures were evaluated in this review, two generic health status 
measures (SF-36 and SF-12) and two preference based measures (EQ-5D and SF-6D). 
 
The measures studied 
The SF-36®  is a generic health status profile measure consisting of eight dimensions of general 
health (GH); bodily pain (BP); physical functioning (PF); role-physical (RP),  mental health (MH); 
vitality (V); social functioning (SF) and role-emotional (RE). These eight dimensions also can be 
used to generate a physical and mental health summary scores. (Ware, Kosinski and Keller, 
1994) The SF-12® (Ware, Kosinski and Keller, 1996) is a shortened version of the SF-36, 
containing 12 SF-36 items, and also produces two weighted summary scores (PCS and MCS).   
 
The EQ-5D valuation questionnaire comprises a five dimensional questionnaire and an EQ-5D 
Visual Analogue Scale (VAS). Respondents are asked to report their level of problems (no 
problems, some/moderate problems or severe/extreme problem) on the questionnaire which 
includes mobility, self-care, usual activities, pain and anxiety/depression, to provide a position on 
the EQ-5D health state classification.  Responses can be converted into one of 243 different 
health state descriptions (ranging from no problems on any of the dimensions [11111] to severe 
problems on all five dimensions [33333]) which each have their own preference-based score. 
Preference-based scores are determined by eliciting preferences i.e. establishing which health 
states are preferred from a population sample. In order to do so, a method such as time trade off 
7 
 
is used which involves asking participants to consider the relative amounts of time (for example, 
number of life-years) they would be willing to sacrifice to avoid a certain poorer health state 
(Tolley, 2009). Utility values from the UK EQ-5D can range from -0.59 to 1, where negative 
values are felt to be worse than death and a value of 1 indicates perfect health (Dolan, 1997). 
These health state utility values can be used to calculate quality adjusted life years (QALYs) for 
cost effectiveness analysis 
The EQ-5D VAS reports on the respondents’ self-rated valuation of their health stated and thus is 
based on the preferences of the patients, but is not preference based and not normally used to 
generate QALYs. 
 
The SF-6D is a preference-based measure of health that can be generated from items of the SF-
36 or SF-12 (Brazier, Roberts and Deverill, 2002; Brazier and Roberts, 2004).  The SF-6D has a 
classification that describes health on six multi-level dimensions of physical functioning, role 
limitations, social functioning, pain, mental health and vitality. There are algorithms for scoring 
each state based on values obtained from general population surveys using standard gamble 
(respondents make a series of choices which allow estimation of the strength of preferences 
regarding a health state).  Health state utility values range from 0.29 to 1.0.  
 
Methods 
Identification of studies 
A literature search was performed to identify relevant research for a wider review including other 
mental health conditions. The search included searching for ‘personality disorders’ using 
database thesaurus and free text terms. Two sets of search terms were combined: terms for 
each of the four HRQL measures AND terms for the personality disorders. (Search strategies are 
available from authors). Ten databases were searched for published research: Cochrane 
Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, NHS 
Economics and Evaluations Database, Health Technology Database, Database of Abstracts of 
Reviews of Effects, MEDLINE, PreMEDLINE, CINAHL, EMBASE, Web of Science. Searches 
were limited to English Language only but not by any date restriction. All searches were 
conducted in August 2009, and update searches were conducted in March 2011 for two 
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conditions (personality disorders and bipolar disorder) to identify new relevant studies.  The 
reference lists of relevant studies were searched for further papers.  
 
Citations identified by the searching process were screening by one reviewer (DP). Studies were 
eligible for inclusion if they contained HRQL data using one or more of the following instruments: 
SF-36, SF-12, SF-6D or EQ-5D within the specified population: adults (18 years +) with a 
personality disorder. HRQL data could be from descriptive systems (i.e. their items and 
dimensions) or health state utility values generated by the EQ-5D or SF-6D or the EQ-5D VAS. 
Studies whose primary focus was on individuals with alcohol and/or drug dependency with a 
comorbid personality disorder were excluded. The outcomes had to include data that allowed 
measurement of the construct validity (i.e. known groups, convergent) or the responsiveness of 
the HRQL instrument (s). The full texts of papers were retrieved for any titles or abstracts that 
appeared to satisfy the inclusion criteria, or for which inclusion or exclusion could not be 
definitely determined. In addition, 10% of citations were double-screened for the wider systematic 
(which included other mental health conditions) at abstract-level. Both reviewers were in 
complete agreement on the decisions made in this sample of citations. Subsequently, the same 
inclusion and exclusion criteria were used to assess full papers by one reviewer (DP) and where 
queries over inclusion arose, these were resolved by discussion and consensus with another 
reviewer (JB). 
 
Data extraction  
Data from all included trials were extracted by one reviewer (DP) using a form designed 
specifically for this review, and piloted on a sample paper. Data extracted included: country of 
publication, type of disorder, study sample characteristics (numbers, age, gender), other 
measures used, mean values for HRQL measures (per population and per collection), type and 
method of validity assessment, type and method of responsiveness assessment and validity and 
responsiveness data.  
 
Evidence synthesis and meta-analysis 
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Due to the heterogeneity of study designs, HRQL instruments and methods of determining 
construct validity and responsiveness, it was not appropriate to perform meta-analysis. Analysis 
was by narrative synthesis and data were tabulated.  
 
Defining validity and responsiveness 
For the purposes of this review, construct validity and responsiveness an HRQL were defined 
and assessed as follows: 
 1) Known groups or extreme groups validity was demonstrated when an HRQL measure was 
able to detect differences in HRQL between two groups who differ in a trait or behavior (Streiner 
and Norman, 2003).  For e.g. HRQL scores in individuals with personality disorders could be 
hypothesised as being lower than that of healthy individuals.   
2) Convergent validity was demonstrated by the relationship an HRQL measure had with other 
measures of the same construct (Streiner and Norman, 2003). Convergent validity was defined 
as the correlation between two measures that in theory are associated. The strength of 
correlation between the two instruments is calculated using statistical tests (for e.g. Pearson's 
product moment correlation, Spearman's rank correlation).  
3) Responsiveness was demonstrated by the extent to which an HRQL measure was able to 
detect a clinically significant or practically important change over time (Walters, 2009). For 
example, this might be demonstrated by strong correlation between change scores on a clinical 
measure and an HRQL measure or by the HRQL being able to detect differences in HRQL 
between patients defined as responders and non-responders.  
 
The application of these psychometric criteria to preference-based HRQL measures requires 
some adaptation (Brazier and Deverill, 1999). The purpose of EQ-5D or SF-6D is to identify all 
differences or changes in health that are important to patients and valued by the general public.  
An item of the EQ-5D, for example, may fail to pick up small differences in one dimension or miss 
another health dimension entirely, but if these are not important to patients and not valued by the 
general population, then it is not a weakness of the instrument. For example, in convergent 
validity, it would be important to use an instrument hypothesised as being likely to have a strong 
relationship to preferences to test convergence of a generic preference based HRQL measure 
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such as the EQ-5D. Similarly, where known groups validity is being tested, the groups in which 
the HRQL measure must detect a difference in scores, must be hypothesised as being likely to 
differ in HRQL.   
 
Results 
The search for studies for the wider review on a range of mental health conditions retrieved 4115 
unique citations (see Figure 1). Of these, 3849 were excluded at the title and abstract stage and 
266 were examined in full-text; of which seven articles on personality disorders met the criteria 
for inclusion in this review. In the update searches, a further 623 unique citations were retrieved, 
and of these 11 were examined at full-text level. A further three studies on personality disorders 
were included in this review from the update searches. In total, ten studies including data on 
personality disorders were included at full-text level.  
 
Study characteristics 
Six studies looked at the EQ-5D (Bartak et al., 2010; Bartak et al., 2011a; Bartak et al., 2011b; 
Soeteman et al., 2005; Soeteman, Verheul and Busschbach, 2008; van Asselt et al., 2009), two 
at the SF-36 (Narud, Mykletun and Dahl, 2005; Hueston, Mainous and Schilling, 1996) and two 
at the SF-12 (corresponding to 3 articles) (Jackson and Burgess, 2000; Jackson and Burgess, 
2002; Sanderson and Andrews, 2002). No studies were found investigating the validity or 
responsiveness of the SF-6D in this patient group. Six studies were undertaken in the 
Netherlands (Bartak et al., 2010; Bartak et al., 2011a; Bartak et al., 2011b; Soeteman et al., 
2005; Soeteman, Verheul and Busschbach, 2008; van Asselt et al., 2009). Two studies were 
undertaken in Australia (Jackson and Burgess, 2002; Sanderson and Andrews, 2002). One study 
was undertaken in Norway (Narud et al., 2005) and one study in the USA (Hueston et al., 1996). 
Nine of the ten studies presented data for different personality disorders together (Bartak et al., 
2010; Bartak et al., 2011a; Bartak et al., 2011b; Soeteman et al., 2005; Soeteman, Verheul and 
Busschbach, 2008; Narud et al., 2005; Hueston et al., 1996; Jackson and Burgess, 2002; 
Sanderson and Andrews, 2002)  . One study looked exclusively at individuals with borderline 
personality disorder (van Asselt et al., 2009).  
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The number of individuals included within the studies that were diagnosed or screened as having 
one or more personality disorders ranged from 48 to 1,708. Participants included males and 
females (proportions can be seen in Table 1). The mean age of participants with personality 
disorders reported in nine of the ten studies ranged between 29.4 to 45 years. The two reports 
on the study by Jackson and Burgess did not provide information on age (Jackson and Burgess, 
2000; Jackson and Burgess, 2002) 
 
Validity and responsiveness  
Two studies investigated the known groups validity of the EQ-5D (Soeteman et al., 2005; 
Soeteman, Verheul and Busschbach, 200); one study investigated the convergent validity of the 
EQ-5D (Soeteman et al., 2005) and four studies investigated the responsiveness of the EQ-5D  
(Bartak et al., 2010; Bartak et al., 2011a; Bartak et al., 2011b; van Asselt et al., 2009). Two 
studies investigated the known groups validity of the SF-36 (Narud et al., 2005; Hueston et al., 
1996) and two studies investigated this property in the SF-12 (Jackson and Burgess, 2002; 
Sanderson and Andrews, 2002). One study investigated the responsiveness, and convergent 
validity of the SF-36 (Narud et al., 2005).  
 
EQ-5D 
Soeteman et al. (2005) looked at the use of the EQ-5D within a group of individuals described as 
having 'complex personality problems and personality disorders', although no formal diagnoses 
are provided. The EQ-5D demonstrated that these individuals had much lower EQ-5D index 
scores in comparison to a non-clinical population (0.54 vs. 0.85). In addition, EQ-5D scores were 
moderately correlated with the Global Severity Index scores (0.49). In another study, Soeteman 
et al. (2008) looked at the use of the EQ-5D within all personality disorders. Having a borderline, 
narcissistic, obsessive-compulsive, depressive, negativistic or personality disorder mixed had a 
significant effect on the EQ-5D score. However, it was the number of personality disorders rather 
than the type of personality disorder that had a large effect on EQ-5D score (p=0.000). When 
controlling for the number of disorders in the linear regression, only depressive personality 
disorder maintained a unique statistically significant effect on QoL (p=0.03).  
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Van Asselt et al. (2009) assessed the responsiveness of the EQ-5D amongst a group of 
individuals with borderline personality disorder (BPD). Three years after baseline in an RCT 
where patients had received one of two types of psychotherapy, the EQ-5D-Index and EQ-VAS 
showed significant moderate correlation (0.487 and 0.404 respectively, p<0.01) with the change 
scores on the Borderline Personality Disorder Severity Index-IV (BPDSI-IV) (a clinical measure of 
the severity of BPD). The EQ-5D was also able to detect differences in patients who recovered 
and had not recovered three-years post-baseline according to change scores on the BPDSI-IV 
(p=0.000). Bartak et al. (2010, 2011a, 2011b) conducted three studies in individuals with cluster 
A (Bartak et al., 2011b), cluster B (Bartak et al., 2011a) and cluster C PDs ((Bartak et al., 2010). 
However, within each study there were substantial numbers of patients who were diagnosed with 
PDs from more than one cluster (see table 1 for details) and thus it was unclear if patients were 
counted twice between the three studies. In the cluster A and B studies, patients were assigned 
to one of three settings for psychotherapeutic treatment (outpatient, day hospital or inpatient). In 
the study investigating Cluster C PDs, patients were allocated to one of five different treatment 
modalities: long-term outpatient treatment, short-term or long-term day hospital treatment or 
short-term or long-term inpatient treatment.  
In each of the three studies, EQ-5D scores were measured pre-and post-treatment per treatment 
group.  Effect sizes were largely moderate to strong when scores pre-and post-treatment were 
compared, thus the EQ-5D Index appears responsive to change in patients. In addition, the EQ-
5D Index was able to detect differences in scores between difference treatment modalities.  
 
SF-36 
Narud et al. (2005) found that the SF-36 could distinguish between individuals with personality 
disorders and age- and gender-adjusted norms (p<0.001). However, there were no significant 
differences in the mean MCS or PCS when patients with one, two or three or more personality 
disorders were compared. Hueston et al. (1996) found that scores were significantly lower in 
individuals screened as high risk of a personality disorder compared with individuals at low risk 
for personality disorder on mental health (p=0.01), physical functioning (p=0.04), role limitations 
due to emotional problems (p=0.03) and general health (p=0.05) dimensions.  
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Narud et al. (2005)found correlations between the SF-36 and clinical and functioning measures 
were weak to moderate. Correlation with the Global Assessment of Functioning (GAF) ranged 
from 0.12 to 0.40, with the Symptom Checklist 90-Revised (SCL-90R) Personality Severity Index 
(PSI) from 0.12 to 0.38 and the Social Adjustment Scale (SAS) as 0.23 to 0.45. In general, 
correlations were stronger between the mental health domains and the measures. However, 
comorbid Axis I disorders explained a significant part of the scores on the MCS (Narud et al., 
2005).  
 
Narud et al. (2005)noted significant improvement on clinical and functioning measures, whilst the 
SF-36 only showed significant improvement on the role limitations due to physical problems and 
mental health dimensions. Considerable but not significant changes were observed for the bodily 
pain.  
 
 
SF-12 
As part of the Australian National Survey of Mental Health and Wellbeing undertaken in 1997, 
SF-12 values were found to be lower in individuals with on or more personality disorders when 
compared with individuals who had no personality disorders (p<0.0001) on both the MCS and 
PCS (Jackson and Burgess, 2000). These data were re-examined at a later date ((Jackson and 
Burgess, 2002)and the authors found that an increase in the number of personality disorders 
reduced the SF-12 MCS (i.e. greater disability), even when controlling for comorbid Axis I 
disorders.  
Sanderson and Andrews (2002) used linear regression to predict the difference in SF-12 scores 
between individuals with personality disorder diagnoses and individuals with no mental health 
disorder, whilst controlling for the influence of sociodemographic variables and co-occurring 
mental and chronic physical conditions. Individuals with personality disorders were 10.6 points 
lower in SF-12 score. There were no data on the responsiveness of the SF-12 within personality 
disorders.  
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Discussion 
Six studies contained data on the EQ-5D, two studies involved the SF-36 and two studies 
contained data on the SF-12. No studies were identified that examined the SF-6D in individuals 
diagnosed or at high risk of personality disorders. The EQ-5D appears responsive in individuals 
with personality disorders. Data on other properties such as convergent and known groups 
validity were very limited. There was also little evidence on the SF-36 or SF-12.  Nevertheless, 
the studies which did exist provided some positive evidence that the measures are valid for use in 
personality disorders. An exception was Narud et al. (2005)who found that most dimensions on 
the SF-36 were not able to detect changes in patients in the same way as clinical measures and 
concluded that this may be because some SF-36 dimensions are not relevant to HRQL so that, 
even if patients change clinically, this does not translate to a change in health related quality of 
life.  
 
There is of course a third conclusion to draw from Narud et al. (2005), that the SF-36 dimensions 
do not capture the aspects of HRQL that are important to patients, and thus can not detect any 
change in those aspects. This review has been limited to examining quantitative evidence. 
However, increasingly researchers and regulatory authorities such as the FDA and EMEA 
(U.S.Department of Health and Human Services Food and Drug Administration CDER & CDRH, 
2009; European Medicines Agency, 2005) also require qualitative evidence on the validity of 
measures in specific patient groups based on interviews with patients. There are studies that 
have examined the concepts important to quality of life from patients’ perspective within mental 
health conditions in general (Mayers, 2000) and within individual conditions such as bipolar 
disorder (Michalak, Kolesar and Lam, 2006) and schizophrenia and other psychotic conditions 
(Cook and Chambers, 2009). These studies have found that individuals with mental health 
conditions regard concepts such as stigma (Michalak, Kolesar and Lam, 2006; Cook and 
Chambers, 2009), lack of personal achievement, loneliness and personal safety (Mayers, 2000) 
as having a big impact on their quality of life. However, such concepts are not incorporated into 
generic HRQL measures.  
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Within personality disorders, we know of just one study which investigated the experiences of 
symptoms, suffering, and life situation in a group of ten individuals with borderline personality 
disorder (Persieus, Ekdahl, Zsberg and Samuelsson, 2005). Rapid mood swings, putting on a 
‘mask or normality’ when feeling very different on the inside, self-hate, and fear relationships or 
fear of life/longing for death were all highlighted by study participants as increasing their suffering. 
Therefore, these are factors, which aren’t directly incorporated in generic HRQL measures and 
are important to consider when measuring HRQL in this patient group.  Nonetheless, they may be 
indirectly reflected in the generic dimensions of these measures (Brazier et al., 2012).  Indeed the 
quantitative evidence reviewed in this paper suggests that these condition specific problems are 
reflected in the generic dimensions, and that it is reasonable to recommend the EQ-5D in 
particular for use in this population.  However, a concern remains that there is an important 
qualitative dimension to some of these PD specific problems that are not being measured.   It is 
possible that qualitative evidence may identify key dimensions which could be ‘added’ onto the 
EQ-5D to improve its content validity. 
 
Despite the paucity of literature on quality of life within personality disorders (Narud et al. 2005); 
Narud and Dahl, 2002) and the limited evidence available on the validity and responsiveness of 
generic HRQL measures, cost-effectiveness analyses using generic preference-based HRQL 
measures have been undertaken and have demonstrated that interventions and therapies in this 
patient group can be cost-effective (Soeteman et al., 2010; van Asselt et al., 2008 and Palmer et 
al., 2006).  More cost effectiveness analyses need to be undertaken within this patient group 
using preference-based measures.  
 
Strengths and limitations 
This review is the first to have comprehensively identified studies that report on the construct 
validity and responsiveness of the EQ-5D, SF-36, SF-12 and SF-6D within personality disorders 
and to tabulate and give a narrative synthesis of the findings. However, the review has some 
limitations. Whilst the search for studies was reasonably comprehensive, it was limited to key 
databases and reference list checking of included studies, and study selection was undertaken by 
one reviewer.  Ideally, further searching could be undertaken in trial registries, conference 
16 
 
proceedings and by citation searching to make the search process more comprehensive. Study 
quality assessment has not been undertaken and there are issues to consider when interpreting 
the findings. Four studies had small sample sizes (N<100) (Bartak et al., 2011b; van Asselt et al.,  
2009; Narud et al., 2005; Hueston et al., 1996) and all but one study (van Asselt et al., 2009) 
presented overall findings for all personality disorders combined. Given the heterogeneous nature 
of different types of personality disorders, this may not be appropriate as HRQL can vary 
according to the type of personality disorder (Cramer, Torgerson and Kringlen, 2006).  In addition, 
the level of co-morbidity with other conditions was reported as high in three studies (Narud et al., 
2005; Hueston et al., 1996; Jackson and Burgess, 2002), although two studies did adjust their 
analyses accordingly. Indeed, Jackson and Burgess (2002) ( found that even where co-
morbidities existed, personality disorders still had an additional  effect on HRQL. Finally, five of 
the ten studies were cross-sectional in design and evidence could be strengthened by 
undertaking more longitudinal studies. Nevertheless, this review gives an overall picture of the 
validity and responsiveness of the HRQL measures within personality disorder.  
 
In conclusion, the limited quantitative evidence available shows that generic HRQL measures, 
including preference-based measures and in particular the EQ-5D, are responsive within this 
patient group. However, further research, particularly on validity and on the SF-6D, would 
strengthen the use of generic HRQL measures within individuals with personality disorders. 
Incorporating qualitative research and the aspects deemed important by patients is also important 
to further examine what may be missing. .  
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 Figure 1: Flow diagram of study identification- see separate file (JPEG) 
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Table 1: Validity and responsiveness of the SF-36, SF-12 and EQ-5D in personality 
disorders.  
Study 
details 
Population (N) and characteristics Measurement and Practical Properties 
 Properties 
measured 
Details of validity or 
responsiveness  
SF-36 
Narud, K 
(2005)(42) 
Norway 
Personality disorders 
N=91 (48 females and 43 males) 
(Mean age= 36.6 (10.5) 
Age range 19 to 74 years 
 
 
Known groups 
validity 
convergent 
validity 
 
Responsiveness 
The SF-36 could distinguish between 
individuals with PDs and age- and 
gender-adjusted norms (p<0.001). 
There were no significant differences 
in the mean MCS or PCS when 
patients with one, two or three or 
more PDs were compared. 
 
Weak to moderate correlation with 
clinical (SCL-90R) and functioning 
measures (GAF, SAS) on the MCS 
mostly, correlations ranged from 
0.12 to 0.45.  
 
Only the role limitations due to 
physical problems and mental health 
dimensions showed significant 
changes post-treatment. 
Hueston, W 
J (1996)(43) 
USA 
Patients ‘at risk’ of PDs: determined by 
completion of the  SCID for DSM-III-R for 
personality disorders 
N=93  
N=65 patients at high risk of one or more 
PDs; Mean age= 44.7 (15.3); 17 males and 
48 females 
N=28 patients at low risk of PDs; Mean 
age= 39.7 (15.1); 6 males and 22 females 
 
 
Known groups 
validity 
 
Scores were significantly lower 
individuals at high risk of personality 
disorder compared with individuals  
at low risk for personality disorder on 
the following SF-36 dimensions: 
 
Mental health (p=0.01); Physical 
functioning (p=0.04); Role limitations 
due to emotional problems (p=0.03) ; 
General health (p=0.05)  
SF-12 
Jackson, H I 
(2000)(44)/ 
Jackson, H I 
(2002)(45) 
Australia 
N=10, 641  
4705 males and 5936 females 
Age data not reported.  
N=704 (319 males and 385 females) had 
at least one PD 
 
Known groups 
validity 
 
The SF-12 could distinguish between 
individuals with or without personality 
disorders. However, further analyses 
indicated this effect may be due to 
comorbid Axis I conditions.  
Sanderson, 
K (2002)(46) 
Australia 
Sample taken from Australian National 
Mental Health and Well-being survey 
(N=10,641)- a nationally representative 
household survey of mental disorders in 
 
 
Known groups 
validity 
Linear regression was used to 
predict the difference in SF-12 
scores between individuals with 
personality disorder diagnoses and 
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Study 
details 
Population (N) and characteristics Measurement and Practical Properties 
 Properties 
measured 
Details of validity or 
responsiveness  
adults. 
 
5214 males and 5427 females 
 
Participants in survey mean age= 45 years 
 
No mental disorder: n=9, 902 
 
Any personality disorder: n=564 
 individuals with no mental health 
disorder, whilst controlling for the 
influence of sociodemographic 
variables and co-occurring mental 
and chronic physical conditions. 
Individuals with personality disorders 
were 10.56 points lower in score.  
 
 
 
EQ-5D 
Bartak, A 
(2011)(38)  
Netherlands 
DSM-IV-TR axis II cluster A personality 
disorders  
N=57 
17 males and 40 females 
Mean age= 29.4 (+/-8.2) 
 
PD diagnosis 
‘Pure’ cluster A, n=9; Cluster A and B n= 7; 
Cluster A and C n= 18 
Cluster A, B and C n=23 
Paranoid PD n= 49; Schizoid PD n=5; 
Schizotypal PD n=4 
 
All received psychotherapeutic treatment in 
one fo three settings: 
Outpatient n=20 
Day hospital n=19 
Inpatient n=18 
 
 
 
Responsiveness 
Effect sizes for the EQ-5D Index 
scores pre- and post- treatment were 
moderate for the outpatient and 
inpatient groups (0.47 and 0.59 
respectively) and strong for the day 
hospital group (0.85). For the EQ-5D 
VAS, the effect sizes were strong for 
the day hospital group and inpatient 
group (1.03 and 0.73 respectively) 
whilst weak for the outpatient group 
(0.04) 
 
When the EQ-5D Index and VAS 
change scores were compared 
across the three treatment groups, 
the Index showed moderate to 
strong effect sizes (outpatient vs. 
day hospital 0.83, outpatient vs. 
inpatient 0.68 and day hospital vs. 
inpatient 0.83). For the EQ-5D VAS, 
the effect sizes were weak for two 
comparisons (outpatient vs. day 
hospital 0.02 and day hospital vs. 
inpatient 0.21). The effect size was 
strong when outpatient vs. inpatient 
VAS scores were compared (0.99). 
Bartak  A 
(2011)(37) 
Netherlands 
DSM-IV-TR axis II cluster B personality 
disorders  
N=207 
70 males and 147 females 
Mean age= 31.3 (SD 8.5) 
 
 
 
Responsiveness 
Effect sizes were weak to strong 
when EQ-5D Index scores were 
compared pre- and post-treatment 
(outpatient 0.37, day hospital 0.72 
and inpatient 0.80) 
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Study 
details 
Population (N) and characteristics Measurement and Practical Properties 
 Properties 
measured 
Details of validity or 
responsiveness  
 
PD diagnosis 
Pure cluster B n=84; Cluster B and C 
n=93; Cluster B and A n=7; Cluster A, B 
and C n=23 
Borderline PD n=160; Narcissistic PD 
n=47; Histrionic PD n=26; Antisocial PD 
n=18 
All received psychotherapeutic intervention 
in one of three settings: 
Outpatient n=46; Day hospital n=81; 
Inpatient n=80 
 
When the change scores of the EQ-
5D Index were compared across the 
three treatment groups effect sizes 
were weak for the comparisons of 
outpatient vs. inpatient (0.16) and 
day hospital vs. inpatient (0.18), 
whilst strong for outpatient vs. day 
hospital (0.71). 
Bartak, A 
(2010)(36)  
Netherlands 
DSM-IV-TR axis II cluster C personality 
disorders 
N=371; 110 males and 261 females; Mean 
age= 33.5 (SD 9.5) 
 
Pure cluster C n=247; Cluster C and B 
n=88; Cluster C and A n=15 
Cluster, C, B, and A n= 21 
 
Avoidant PD n=235; Obsessive-
compulsive PD n= 183; Dependent PD= 84 
 
All received one of five modalities of 
psychotherapeutic interventions  
Long outpatient  n=68; Short day hospital 
n=77;Long day hospital n=74;Short 
inpatient n=59; Long inpatient n=93 
 
 
Responsiveness 
Effect sizes for the pre- and post- 
EQ-5D Index scores were strong for 
the Long day hospital and  Short 
inpatient treatment groups (0.90 and 
1.21 respectively) moderate for the 
Long inpatient and long outpatient 
treatment groups (0.67and 0.74 
respectively) and weak for the short 
day hospital treatment group (0.37).  
 
EQ-5D scores also improved 
significantly more in the short-term 
inpatient group than in 2 other 
groups: the short-term day hospital 
group (β= 0.15, p=0.0009, 95% CI 
0.06-0.23) and the long-term 
inpatient-group (β=0.11, p=0.0113, 
95% CI 0.03-0.19) 
Soeteman, 
D I 
(2005)(39) 
Netherlands 
Complex personality problems or 
personality disorders 
N=1, 651 (541 male and 1110 female) 
Mean age= 31.9 years (SD=9.2) 
Age range 18 to 61 years 
 
Known groups 
validity 
 
Convergent 
validity 
Substantial differences in EQ-5D 
scores between a nonclinical 
population and the study population. 
Moderate correlation with a 
functioning measure (GSI).  
Soeteman, 
D I 
(2008)(40) 
Netherlands 
N=1, 708 (605 males and 1103 females). 
Mean age= 33.7 years (SD=9.9) Age 
range= 18 to 67 years 
 
- 
Known groups 
validity 
The greater the number of 
personality disorders, the worse the 
EQ-5D score (p=0.000) 
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Study 
details 
Population (N) and characteristics Measurement and Practical Properties 
 Properties 
measured 
Details of validity or 
responsiveness  
Van Asselt, 
A D 
(2009)(41) 
Netherlands 
Borderline personality disorder 
N= 48 ; Mean age of completers was 31 
years (SD=8.55); 43 females and 5 males.  
 
 
Responsiveness 
Able to detect difference between 
patients who had recovered and not 
recovered three years post baseline. 
Also showed moderate correlation 
with change scores on a severity 
index (BPDSI-IV)  
BPDSI-IV = Borderline Personality Disorder Severity Index-IV; GAF= Global Assessment of functioning ; GSI=Global 
Severity Index; SAS= Social adjustment scale; SCID= Structured Clinical Interview; SCL-90R= Symptom checklist 90-
Revised 
